CNBC Investing Club: Cramer’s Morning Take on Microsoft 3/23/26

Carl Quintanilla (0:00)

Thy ticket, Lady Jennifer of Coolidge.

SPEAKER_2 (0:03)

Well, many thanks, good sir.

SPEAKER_3 (0:05)

Heareth my Discover card.

SPEAKER_4 (0:08)

They accept Discover at Renaissance Fairs?

Carl Quintanilla (0:10)

Yeah, they do here.

SPEAKER_4 (0:12)

Discover is accepted at the places I love to shop.

Carl Quintanilla (0:15)

Getteth with the times. With the times?

SPEAKER_2 (0:18)

You're playing the lute. Yeah, and it sounds pretty good, right?

SPEAKER_4 (0:23)

Discover is accepted at 99% of places that take credit cards nationwide. Based on the February 2025 Nielsen Report.

SPEAKER_2 (0:30)

This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Join host Keith Lansford for this information-packed daily market preview delivered in 10 minutes or less, including projected stock updates, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com/marketupdatepodcast or find Schwab Market Update wherever you get your podcasts.

Jim Cramer (1:01)

Jim Cramer here to share a short preview of my take on the market from today's members-only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 1020 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take.

Carl Quintanilla (1:22)

We downgraded this the other week but Mellius is tough on Microsoft too. They lower their price target to 400

Jim Cramer (1:28)

Do you know that it really is the ghost of alphabet that keeps me from saying, you know what, I'm done. I can't fight it because down 20 percent. The reason I say that is because you're not dealing with a company that has no means. It's an incredibly rich company. You're not dealing with a company that has bad management. It's among the best management in the whole S&P.

Carl Quintanilla (1:51)

You've likened it to Google when they first rolled out BARD. That was a huge whiff, a big miss versus CHAP GPT and the other AI models. But Gemini has taken leadership and Alphabet has figured out its full AI stack. Meanwhile, Microsoft, there was reports last week reorganizing copilot. Melia is saying, you don't do this into strength. This is weakness. But maybe it's something they need to do.

Jim Cramer (2:18)

Well, let's say they decided, we're going to go all AI and we're going to lay off 50,000 people. That stock goes higher, not lower. I think that that's a company that has the balance sheet to do that.

Carl Quintanilla (2:34)

Some other big stories today. Synopsis is Elliott management takes a multi-billion dollar stake pushing for changes like raising prices.

Jim Cramer (2:40)

The stock should be up more. I'll tell you why. Synopsis' gross margins are substantially lower than its competitor cadence. The company has not raised price even in an environment where they bought Ansys and they could raise price. They can now go to their customers and say, look, well, you know we've tried to keep prices down, but we've got Elliott breathing down our neck and that's just a brilliant situation. I think it's going to happen.

SPEAKER_3 (3:05)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_4 (3:37)

Snoring, gasping during sleep, feeling fatigued? Wake up to ZepBound Terzepatide, the first and only FDA approved prescription medicine for moderate to severe obstructive sleep apnea, OSA and adults with obesity. ZepBound is an injectable prescription medicine that may help adults with moderate to severe obstructive sleep apnea, OSA and obesity to improve their OSA. ZepBound should be used with a reduced calorie diet and increased physical activity. ZepBound is approved as a 2.5, 5, 7.5, 10, 12.5 or 15-milligram injection. ZepBound contains terzepotide and should not be used with other terzepotide-containing products or any GLP-1 receptor agonist medicines. It is not known if ZepBound is safe and effective for use in children. Do not share needles or pens or reuse needles. Don't take ZepBound if allergic to it or if you or someone in your family had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 Tell your doctor if you get a lump or swelling in your neck. Stop ZepBound and call your doctor if you have severe stomach pain or a serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes, depression or suicidal thoughts before scheduled procedures with anesthesia, if you're nursing, pregnant, planned to be or taking birth control pills. Taking ZepBound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor. Call 1-800-545-5979 or visit zepbound.lily.com. ZepBound and its delivery device base in QuickPin are registered trademarks owned or licensed by Eli Lilly and company, its subsidiaries or affiliates.